King’s College London has announced that it has recently entered into an exclusive license agreement with Pfizer Inc. for the development of a series of adeno-associated virus (AAV) gene therapy vectors
In the biggest sign yet that the era of blockbuster drug is drawing to a close, Pfizer this week announced the creation of a new research unit focused on rare diseases.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.